Consistent with our results, Toi et al. suggested that PSO (100–200 μg/mL) provided a significant decrement in VEGF levels in estrogen‐sensitive (MCF‐7) or estrogen‐resistant (MDA‐MB‐231) human breast cancer cells (Toi et al., 2003). Here, VEGFA is linked to breast carcinoma.